MRK stock news & analysis

Market briefs on MRK

• S&P 500 Falls 1.8% Ahead of Midterms as AI Worries Grow

  The S&P 500 (SPX) closed at 7,580 as traders weighed a likely Democratic Congress for defense, drugs and AI

  Nov 1

• Eli Lilly Stock Jumps 4% Premarket After Earnings Beat

  Eli Lilly (LLY) sales hit $24.4B, up 39%, while Merck (MRK) beat forecasts as Keytruda sales rose 6%.

  Oct 29

• Moderna Stock Falls 17% After Cancer Vaccine Data Leak

  Moderna (MRNA) slid another 1.3% Friday to $200 as investors weighed a 42% cut in melanoma recurrence risk.

  Oct 26

• Moderna Stock Falls 25% After Melanoma Vaccine Data Leak

  Moderna (MRNA) fell as Merck slipped up to 3.9% after leaked data showed a 42% lower melanoma relapse risk.

  Oct 22

• Moderna Stock Rises 4.4% as ESMO Cancer Vaccine Data Nears

  Moderna (MRNA) is up over 600% this year after joining the Nasdaq-100, with Phase 3 data due Saturday.

  Oct 19

• Pharma Stocks Jump 4% After Trial Results, Deals

  Eli Lilly (LLY), Merck (MRK) and AstraZeneca (AZN) beat a falling market as hot inflation hit tech stocks

  Oct 14

• Moderna and Novavax jump 14–16% on Friday as biotech rallies on a federal cancer-vaccine push

  The Friday gains came days after a plague-scare spike faded. Sources tie them mainly to a report on a national cancer-vaccine effort, not to the Russian plague case or Vaxcyte's trial result.

  Oct 12

• Moderna Stock Rises 4.8% as Nasdaq-100 Entry Nears

  Moderna (MRNA) is up more than 540% in 2026 as investors await Phase 3 cancer vaccine data on Oct. 24.

  Oct 8

• Moderna (MRNA) Stock Jumps 7%: Latest News Before Cancer Data

  Moderna (MRNA) is up nearly 600% in 2026 as traders position for full October 24 melanoma trial results. Latest MRNA stock news and what to watch.

  Oct 5

• Vaxcyte Stock Jumps 31% After Positive Phase 3 Data

  Vaxcyte (PCVX) closed at $73.82 as its VAX-31 shot held up against Pfizer's and Merck's shots in a large trial

  Oct 5

• Moderna Stock Falls 6% After Citi Downgrade to Sell

  Moderna (MRNA) sank from $203.46 to about $191 as Citi said a 222% rally assumes unrealistic cancer sales.

  Sep 30

• Pharma Tariffs Hit 100% on Drugmakers Without Pricing Deals

  The 100% tariff now hits drugmakers without pricing deals; Pfizer (PFE) and 16 peers are exempt to 2029.

  Sep 30